Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6V3R

Crystal structure of murine cycloxygenase in complex with a harmaline analog, 4,9-dihydro-3H-pyrido[3,4-b]indole

Summary for 6V3R
Entry DOI10.2210/pdb6v3r/pdb
DescriptorProstaglandin G/H synthase 2, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, PROTOPORPHYRIN IX CONTAINING FE, ... (7 entities in total)
Functional Keywordsprostaglandin g/h synthase 2, cyclooxygenase-2, oxidoreductase, inhibitor complex, membrane protein, oxidoreductase-inhibitor complex, oxidoreductase/inhibitor
Biological sourceMus musculus (Mouse)
Total number of polymer chains4
Total formula weight277204.12
Authors
Xu, S.,Uddin, M.J.,Banerjee, S.,Marnett, L.J. (deposition date: 2019-11-26, release date: 2020-02-26, Last modification date: 2024-11-13)
Primary citationUddin, M.J.,Xu, S.,Crews, B.C.,Aleem, A.M.,Ghebreselasie, K.,Banerjee, S.,Marnett, L.J.
Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors.
Acs Med.Chem.Lett., 11:1881-1885, 2020
Cited by
PubMed Abstract: We report the design, synthesis, and evaluation of a series of harmaline analogs as selective inhibitors of 2-arachidonylglycerol (2-AG) oxygenation over arachidonic acid (AA) oxygenation by purified cyclooxygenase-2 (COX-2). A fused tricyclic harmaline analog containing a CHO substituent at C-6 and a CH group at the C-1 position of 4,9-dihydro-3-pyrido[3,4-]indole (compound ) was the best substrate-selective COX-2 inhibitor of those evaluated, exhibiting a 2AG-selective COX-2 inhibitory IC of 0.022 μM as compared to >1 μM for AA. The 2.66 Å resolution crystal complex of COX-2 with compound revealed that this series of tricyclic indoles binds in the cyclooxygenase channel by flipping the side chain of L531 toward the dimer interface. This novel tricyclic indole series provides the foundation for the development of promising substrate-selective molecules capable of increasing endocannabinoid (EC) levels in the brain to offer new treatments for a variety of diseases, from pain and inflammation to stress and anxiety disorders.
PubMed: 33062168
DOI: 10.1021/acsmedchemlett.9b00555
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.66 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon